FRNRX
Price
$42.82
Change
+$0.30 (+0.71%)
Updated
Jul 13 closing price
Net Assets
487.82M
MDGRX
Price
$34.50
Change
+$0.17 (+0.50%)
Updated
Jul 13 closing price
Net Assets
194.38M
Interact to see
Advertisement

FRNRX vs MDGRX

FRNRX vs MDGRX Comparison Chart in %
View a ticker or compare two or three
VS
FRNRX vs. MDGRX commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FRNRX is a Buy and MDGRX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FRNRX has more cash in the bank: 488M vs. MDGRX (194M). MDGRX pays higher dividends than FRNRX: MDGRX (1.77) vs FRNRX (1.47). FRNRX was incepted earlier than MDGRX: FRNRX (31 years) vs MDGRX (32 years). MDGRX (1.16) is less costly to investors than FRNRX (1.01). MDGRX is a more actively managed with annual turnover of: 90.00 vs. FRNRX (19.72). FRNRX (6%) and MDGRX (5%) have equivalent initial investment costs. FRNRX (1000) and MDGRX (1000) have matching initial minimum investment requirements. FRNRX annual gain was more profitable for investors over the last year : 36.70 vs. MDGRX (14.96). FRNRX return over 5 years is better than : 121.43 vs. MDGRX (37.85).
FRNRXMDGRXFRNRX / MDGRX
Total Expense Ratio1.001.1686%
Annual Report Gross Expense Ratio1.011.1687%
Fund Existence31 years32 years-
Gain YTD16.3979.331176%
Front Load6%5%105%
Min. Initial Investment10001000100%
Min. Initial Investment IRAN/AN/A-
Net Assets488M194M252%
Annual Yield % from dividends1.471.7783%
Returns for 1 year36.7014.96245%
Returns for 3 years56.9023.30244%
Returns for 5 years121.4337.85321%
Returns for 10 years82.972.163,849%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BGI0.55N/A
-0.04%
Birks Group
LAZ41.10-0.31
-0.75%
Lazard
EME764.90-16.88
-2.16%
EMCOR Group
CRBP9.04-0.64
-6.61%
Corbus Pharmaceuticals Holdings
DSGN13.85-1.33
-8.79%
Design Therapeutics